Amylyx expects Q4 and FY 2022 revenue to meaningfully exceed consensus on higher RELYVRIO demand

Amylyx Pharmaceuticals, Inc.

Insurers covering ~25% of U.S. covered lives have published policies; nearly all provide broad access to RELYVRIO.
EU decision on AMX0035 marketing authorization for ALS expected first half 2023; CHMP SAG meeting this month.
Phase 3 PHOENIX trial (664 participants) completed enrollment; topline results anticipated mid-2024.
Starting Feb 19, pharmacy network data will no longer flow to third-party data vendors (closed network model).
Company provides update at SVB Securities conference; Q4 and FY 2022 financial results call in early March 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.